Gepirone

Gepirone
Systematic (IUPAC) name
4,4-Dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione
Clinical data
Routes of
administration
Oral
Pharmacokinetic data
Biological half-life 2-3 hours
Identifiers
CAS Number 83928-76-1
ATC code N06AX19 (WHO)
PubChem CID 55191
ChemSpider 49836 YesY
UNII JW5Y7B8Z18 YesY
ChEMBL CHEMBL284092 YesY
Chemical data
Formula C19H29N5O2
Molar mass 359.46586 g/mol
  (verify)

Gepirone (INN) (developmental code names BMY-13805, MJ-13805, ORG-13011, TGFK07AD; proposed brand names Ariza, Variza) or gepirone hydrochloride (USAN) is an antidepressant and anxiolytic drug of the azapirone group that has never been marketed. Like other azapirones, it acts as a selective partial agonist of the 5-HT1A receptor. Gepirone was under development in the U.S. in an extended release form, but despite completing phase III clinical trials, it failed to pass the drug approval process. As a result, gepirone, despite already having brand names chosen, did not manage to reach the pharmaceutical market.

Gepirone was originally developed by Bristol-Myers Squibb, but was out-licensed to Fabre-Kramer in 1993. The U.S. Food and Drug Administration (FDA) rejected approval for gepirone in 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2004. However, in 2007 it once again failed to convince the FDA of its qualities for treating anxiety and depression. In December 2015, the FDA once again gave gepirone a negative review for depression due to concerns of efficacy.

See also

References



    This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.